| Literature DB >> 31052309 |
Zahra Tavakolian-Ardakani1,2, Oana Hosu3,4, Cecilia Cristea5, Mohammad Mazloum-Ardakani6, Giovanna Marrazza7,8.
Abstract
Neurotransmitters are endogenous chemical messengers which play an important role in many of the brain functions, abnormal levels being correlated with physical, psychotic and neurodegenerative diseases such as Alzheimer's, Parkinson's, and Huntington's disease. Therefore, their sensitive and robust detection is of great clinical significance. Electrochemical methods have been intensively used in the last decades for neurotransmitter detection, outclassing more complicated analytical techniques such as conventional spectrophotometry, chromatography, fluorescence, flow injection, and capillary electrophoresis. In this manuscript, the most successful and promising electrochemical enzyme-free and enzymatic sensors for neurotransmitter detection are reviewed. Focusing on the activity of worldwide researchers mainly during the last ten years (2010-2019), without pretending to be exhaustive, we present an overview of the progress made in sensing strategies during this time. Particular emphasis is placed on nanostructured-based sensors, which show a substantial improvement of the analytical performances. This review also examines the progress made in biosensors for neurotransmitter measurements in vitro, in vivo and ex vivo.Entities:
Keywords: electrochemical; enzyme; neurotransmitter; sensor
Mesh:
Substances:
Year: 2019 PMID: 31052309 PMCID: PMC6539656 DOI: 10.3390/s19092037
Source DB: PubMed Journal: Sensors (Basel) ISSN: 1424-8220 Impact factor: 3.576
Classification of neurotransmitters, biological function and chemical structures [3].
| Category | Neurotransmitter | Biological Function | Chemical Structure |
|---|---|---|---|
| Amino acid | Glutamate | cognition, memory and learning processes |
|
| Tyrosine | regulation of energy balance, memory, learning |
| |
| Biogenic amines | Dopamine | responsible for feelings of pleasure |
|
| Epinephrine | leading to a physical boost and heightened awareness |
| |
| Norepinephrine | improving attention and the speed at which responsive actions occur |
| |
| Serotonin | regulating mood, sleep, emesis, sexuality, appetite, pain |
| |
| Tryptamine | acting in central nervous system and gastrointestinal tract |
| |
| Acetyl choline | Acetylcholine | thought, learning and memory |
|
| Soluble gases | Nitric oxide | cognitive functions, homeostatic functions, neurosecretion and synaptic plasticity |
|
| Hydrogen sulphide | neuromodulator in the brain |
|
Sensors for neurological biomarkers detections.
| Neurological Biomarker | Electrode Surface | Linear Range; | Sensitivity | Technique | Electrolyte | Real Samples/Storage | Interferences | Ref. |
|---|---|---|---|---|---|---|---|---|
| Dopamine | rGO/Bi2S3/GCE | 0.01–40; | 2.046 µA µM−1 | CV–DPV | 0.1 M PBS pH 6.0 | Urine samples/30 days (91.6%) | Ca2+, Na+, Li+, Cu2+, Cl−, SO42−, phenacetin, Glu, Fru, caffeine, APAP, Cys, Tyr, proline, AA, UA | [ |
| rGO-poly(FeTFPP)/GCE | 0.05–300; | 0.039 µA µM−1 | CV–DPV-EIS | 0.1 M PBS pH 6.0 | Lake water; urine samples/long-term stability (90.2–93.6%) | Na+, Li+, Ca2+, Cl−, SO42−, Glu, Mal, Fru, Lac, AA, UA | [ | |
| rGO/PU | 1 × 10−4–11.5 × 10−4; | 0.011 µA pM−1 | CV-DPV | 0.05 M PBS pH 7.0 | Human serum, | Fe3+, Zn2+, 4-NP, AA, UA, Tyr, Trp, GSH, Glu | [ | |
| PGr/GCE | 0.01–50; | 0.478 µA µM−1 | CV-DPV | 0.1 M PBS pH 7.0 | Human blood/30 days (89%) | AA, UA | [ | |
| 0.005–1; | 0.004 µA µM−1 | Simultaneous detection of DA and AA | ||||||
| rGO-Cu2O/GCE | 10–900; | 0.520 μA μM−1 cm−2 | CV-DPV | 0.1 M PBS pH 7.0 | Human blood; urine/15 days (85%) | UA, AA, Glu, K+, Na+, Cl−, SO42− | [ | |
| rGO/ZIF-8/GCE | 0.1–100; | 0.153 μA μM−1 | CV-DPV | 0.1 M PBS pH 7.0 | Human serum/15 days (95.7%) | AA | [ | |
| HNP-AuAg/GCE | 5–335; | 0.399 μA μM−1 cm−2 | CV-DPV-Amp | 0.1 M PBS pH 7.0 | -/ | AA / | [ | |
| N-G/NiTsPC/GCE | 0.1–200; | 0.089 μA μM−1 | Amp-CV-EIS | 0.1 M PBS pH 7.4 | - / | AA, UA | [ | |
| poly-FA/MWCNT/GCE | 5.00–120.0; | 0.037 μA μM−1 | Amp-CV | 0.1 M PBS pH 7.0 | Pharmaceutical samples/- | 5-HT, AA, UA/Simultaneous detection of DA, NADH and EP | [ | |
| NiO NP-MWCNT-DHP/GCE | 0.07–4.8; | 3.800 μA μM−1 | DPV-SWV | 0.2 M PBS pH 7.0 | Cerebrospinal | - / | [ | |
| HNP-PtTi/GCE | 0.004–500; | 0.186 μA μM−1 cm−2 | CV-DPV-Amp | 0.1 M PBS pH 7.0 | Human serum/- | Na+, K+, Fe3+, Cu2+, Al3+, Glu, and H2O2 / | [ | |
| CPE/GO | 0.08–2.30; | 0.489 μA μM−1 | CV-DPV-LSV | 0.2 M Britton–Robinson buffer pH 4.0 | Human blood/15 days (95.75%) | Na+, NH4+, NO3−, Cl−, CO32−, K+, I−, phenylalanine, Cys, Trp/Simultaneous detection of DA in the presence of Tyr | [ | |
| CE | 0.4 – 100; 2 × 10−1 | 2.292 μA μM−1 cm−2 | CV-DPV | 0.1 M PBS pH 7.0 | Human serum/14 days (95%) | Citric acid, Glu, Cys, | [ | |
| NiO-CuO/GR/GCE | 0.5–20; | 9.406 μA μM−1 cm−2 | EIS-SWV | 0.1 M PBS pH 8.0 | Human serum, blood, pharmaceutical samples/30 days (95%) | K+, Na+, Zn2+, NO3−, Cl−, SO42−/ | [ | |
| GR/p-AHNSA/SPCs | 0.05–100; | 0.099 μA μM−1 | CV-EIS-SWV | 0.1 M PBS pH 7.2 | Human plasma, urine, pharmaceutical samples/- | AA, UA, Trp/Simultaneous detection of DA and 5-HT | [ | |
| [AMIM][BF4]/CCE | 0.1–20; | 1.356 μA μM−1 | CV-DPV | 0.1 M PBS pH 7.0 | Human blood serum, urine, pharmaceutical samples/20 days (96.6%) | Ca2+, Mg2+, Zn2+, Fe3+, K+, NO2−/ | [ | |
| CB-chit/GCE | 0.1–1400; | 0.132 μA μM−1 | CV-DPV | 0.1 M PBS pH 7.4 | Human urine, pharmaceutical samples/- | -/ | [ | |
| Epinephrine | Paraffin/MWCNT/CoPc | 1.33–5.50; | 5.920 μA μM−1 | DPV | 0.2 M PBS pH 6.0 | Human urine samples/(1000 determinations) | UA | [ |
| poly-FA/MWCNT/GCE | 73.0–1406; | 0.004 μA μM−1 | Amp-DPV | 0.1 M PBS pH 7.0 | Pharmaceutical samples/- | 5-HT, AA, UA/Simultaneous detection of DA, NADH and EP | [ | |
| EDDPT/GO/CPE | 1.5–600; | 0.076 μA μM−1 | DPV-Amp | 0.1 M alkaline solution pH 7.0 | Human serum, pharmaceutical samples/7 days (92%) | K+, Na+, Mg2+, Cl−, Glu, Fru, folic acid | [ | |
| NiONP-MWCNT-DHP/GCE | 0.3–9.5; | 0.390 μA μM−1 | DPV-SWV | 0.2 M PBS pH 7.0 | Cerebrospinal | -/Simultaneous detection of DA, and EP | [ | |
| Glutamate | Pt/NiNAE | 500–800; | 0.096 μA μM−1 cm−2 | Amp-CV | 1 M NaOH | -/60 days (90%) | AA, UA, Glu | [ |
| Norepinephrine | AuNPs/ITO | 0.1–25; | 1.011 μA μM−1 | SWV-CV | 0.1 M PBS pH 7.2 | Human blood, urine/7 days (96.3%) | DA, UA, AA | [ |
| Oxytocin | BDDE | 1–10; 5 × 10−2 | - | Amp-CV | 0.1 M PBS pH 7.4 | - | -/Selective detection of oxytocin and vasopresin | [ |
| Serotonin | GR/p-AHNSA/SPCs | 0.05–150; | 0.101 μA μM−1 | CV-EIS SWV | 0.1 M PBS pH 7.2 | Human plasma, urine, pharmaceutical samples/- | AA, UA, Trp/Simultaneous detection of DA and 5-HT | [ |
| PEDOTNTs/rGO/Ag NPs/GCE | 0.01– 500; | 0.0143 μA μM−1 cm−2 | Amp-CV-DPV | 0.1 M PBS pH 7.4 | Bovine assayed multi-sera/30 days (97%) | Cys, Trp, Ala, Glu, DA, EP and NE/ Simultaneous detection of 5-HT in the presence of AA, UA, Tyr | [ | |
| AuAgNPs/GR/ITO | 0.0027–4.82 1.6 × 10−3 | 0.766 μA μM−1 cm−2 | Amp-CV | 0.1 M PBS pH 7.4 | Human serum/19 days (88%) | Glu, K+, Cl-, UA, AA/- | [ | |
| Tryptamine | GCE | 0.047–0.545 | 3.1 μA μM−1 | SWADdSV | 0.1 M Acetate buffer pH 5.3 | Food samples/- | Putrescine/- | [ |
* 4-NP–4-nitrophenol; 5-HT–serotonin; AA–ascorbic acid; [AMIM][BF4]–1-allyl-3-methylimidazolium tetraflouroborate; Ala–alanine; Amp–chronoamperometry; ANI–aniline; APAP–acetaminophen; BBDE–boron-doped diamond electrode; CB–carbon black; Chit–chitosan; CE–carbon electrode; Cor–cortisol; CoPc–cobalt phthalocyanine; CPE–carbon paste electrode; CV–cyclic voltammetry; Cys–cysteine; DHP–dihexadecylphosphate; DPV–differential pulse voltammetry; EDDPT–2-(5-ethyl-2,4-dihydroxyphenyl)-5,7-dimethyl-4H-pyrido[2,3-d][1,3]thiazine-4-one; EIS–electrochemical impedance spectroscopy; FA–ferulic acid; FeTFPP–5,10,15,20-tetrakis(pentafluorophenyl)−21H,23H-porphyrin iron (III) chloride; Fru–fructose; GCE–glassy carbon electrode; GDE–graphite disk electrode; Glu–glucose; GO–graphene oxide; GR–graphene; GSH–glutathione, HNP–hierarchical nanoporous; Lac–lactose; LSV–linear sweep voltammetry; Lys–lysine; Mal–maltose; MrGO–magnetic functionalized reduced graphene oxide; MWCNTs–Multi walled carbon nanotubes; Naf–Nafion; NiNAE–—nickel nanowire array electrode; p-AHNSA–poly-4-amino-3-hydroxy-1-naphthalenesulfonic acid; PEDOT–poly(3,4 ethylenedioxythiophene; PPDpoly (phenylene diamine); PEDOTNTs–Poly(3,4-ethylenedioxythiophene) nanotubes; PU–Polyurethane; rGO–reduced graphene oxide; SPCs–screen-printed cells; SWADSV–square wave adsorptive stripping voltammetry; SWV–square wave voltammetry; Trp–Tryptophan; Tyr–tyrosine; VACNTs–vertically aligned carbon nanotubes; ZIF–8-zeolitic imidazolate.
Figure 1The schematic illustration of in-situ synthetic route of rGO/Bi2S3 composites and the electrocatalysis of DA at rGO/Bi2S3/GCE. Reprinted from [70] with permission of Elsevier.
Figure 2Scheme fabrication process of the biomimetic sensor and the catalytic process for the oxidation of dopamine. Reprinted from [71] with permission of Elsevier.
Figure 3Scheme of fabrication and application of the AuAg-GR nanohybrid material for 5-HT detection. Reprinted from [92] with permission of Elsevier.
Figure 4Schematic representation of main different methods for enzyme immobilization. Reprinted from [109] with permission of Elsevier.
Enzymatic biosensors for neurological biomarkers detections.
| Neurological | Electrode Surface | Linear Range; LOD (µM) | Sensitivity | Technique | Electrolyte | Real Samples/Storage | Interferences | Ref. |
|---|---|---|---|---|---|---|---|---|
| Acetylcholine | SPCE/AuNPs/pTTBA-AChE | 7 × 10−4 −60; | 0.019 µA µM−1 | Amp-CV-EIS | 0.1 M PBS pH 7.4 | Human plasma samples and cell line/60 days (91%) | AA, UA, catechol, GABA, APAP, DA, EP, glutamine | [ |
| AChE/hPG/ Pt | 240–1900; | 0.003 μA µM−1cm−2 | CV-Amp-DPV-SWV | 0.01 M Glycine pH 7.4 + 0.1 M of NaCl | - | - | [ | |
| GCE/Chit-MWCNTs-Fe3O4NPs/AChE-ChOx | 0.02–0.11; | 5.890 µA µM−1 | Amp-CV-EIS | 0.05 M PBS pH 7.5 | Human serum samples/30 days (60%) | AA, UA, APAP, Cys, Glu | [ | |
| Dopamine | HRP/MWCNTs | 32–44; | 1.980 µA µM−1 | CV-DPV-SWV | 0.25 M PBS pH 6.5 | Pharmaceutical samples/Freezing 48 h (99.66%) | AA, UA | [ |
| Tyr/ NiONPs/ITO | 2–200; | 0.060 µA µM−1 | CV | 0.05M | Fetal bovine serum samples/45 days (77%) | AA, UA | [ | |
| rGO/β-CD-Py/GCE | 0.027–38.6; | 0.012 μA µM−1cm−2 | Amp | 0.1M PBS pH 6.5 | - | AA, UA, Glu | [ | |
| Glutamate | GlDH-Th-SWCNTs/GCE | 0.5–400; | 0.137 μA µM−1 cm−2 | CV-Amp | 0.1 M PBS pH 8.3 | -/14 days (93%) | AA, UA, APAP | [ |
| GlOx/ MWCNT/PPy/Pt | 0.3–140; | 0.384 μA µM−1 cm−2 | Amp | 0.1 M PBS pH 7.4 | -/30 days (70%) | AA, UA, APAP | [ | |
| GlOx/MWCNT/PAMAM/Pt/ Nafion | 1.0–50.0; | 0.002 μA µM−1 | Amp-LSV | aCSF pH 7.4 | Artificial cerebrospinal fluid/14 days (86%) | AA, DA/In vivo measurement of glutamate in the striatum of rats | [ | |
| GlDH/VACNTs | 0.1–20; | 0.976 µA µM−1 cm−2 | CV-DPV | 0.1 M PBS pH 7.0 | -/14 days (80.5%) | AA, UA | [ | |
| GlOx/IrOx-MEA | 5–300; | 0.007 × 10−3 µA µM−1 | Amp | PBS pH 7.2 | -/14 days (71%) | AA, DA/In vitro and in vivo glutamate sensing | [ | |
| CeO2/TiO2/GlOx/Chit/oPD/Pt | 5–50; | 0.793 × 10−3 µA µM−1 | Amp | 0.1 M PBS pH 7.4 | Artificial cerebrospinal fluid/20 days (55%) | AA, DA, l-DOPA, 5-HT | [ | |
| CFE/PoPD/GlOx/Gluth | 0–150; | 0.135 µA µM−1 cm−2 | Amp | 0.1 M PBS pH 7.4 | -/30 days (90%) | Glu, lactate, 5-HT, glutamine, UA, AA | [ | |
| GlOx/ZnONRs/PPy/PGE | 0.02–500; | - | CV | 0.1 M Tris–HCl pH 8.5 | Food samples/90 days (70%) | - | [ | |
| MWCNT-Chit-Mel B/GLDH-NAD+-Chit/MWCNT-Chit | 7.5–105; | 0.390 × 10−3 µA μM−1 | CV-Amp | 0.075 M PBS pH 7.0 | Fetal bovine serum sample, food samples; | AA | [ | |
| SHL-GlDH/oxygen electrode | 10–1500; | 0.087 × 10−3 µA μM−1 | Amp | 0.1 M Tris–HCl pH 8.0 | - /14 days (≈100%) | AA, UA, 19 amino acids | [ | |
| HBH-GlDH/oxygen electrode | 10–1500; | 0.089 × 10−3 µA μM−1 | Amp | 0.1 M PBS pH 6.5 | - /7 days (70%) | AA, UA, 19 amino acids | [ | |
| GlOx/PtNP/NAE | Up to 800; | 0.011 μA μM−1 cm−2 | Amp | 0.01 M PBS pH 7.4 | -/14 days (98%) | - | [ | |
| GlDH-Chit-MelB/SPCE | 12.5–150; | 0.037 μA μM−1 | Amp | 0.075 M PBS pH 7.0 | Fetal bovine serum sample, food samples; | - | [ | |
| GlOx/cMWCNTs/AuNPs/Chit/ AuE | 5–500; | 0.155 μA μM−1 cm−2 | CV-EIS | 0.1 M PBS pH 7.5 | Human serum samples;/4 months | AA, UA, Glu, bilirubin, urea, triglycerides | [ | |
| GlDH/Ni-Pd-PAM/GCE | 5–500; | 4.768 μA μM−1 cm−2 | CV-EIS-DPV | 0.1 M PBS pH 7.4 | Food samples; | AA, Cys, l-aspartate | [ | |
| GlOx-PPyNPs/PANI/AuE | 0.02–400; | 0.533 μA μM−1 cm−2 | CV-EIS | 0.1 M PBS pH 7.5 | Food samples; | AA, Glu, citric acid, Cys, methionine, lysine, aspartic acid, NaCl, glycine | [ | |
| GlOx/PPD/Pt microelectrode | 0.5–100 | 0.279 μA μM−1 | Amp | 0.1 M PBS pH 7.4 | Artificial cerebrospinal fluid;/5 months (95%) | l-glutamine, l-aspartic acid, AA, DA, UA, 5-HT, catechol/In vivo glutamate sensing | [ | |
| Quinolinic acid | BSA/QPRT/rGO/ITO | 6.5–65,000 | 7.860 × 103 μA μM−1 cm−2 | CV-DPV | PBS pH 7.0 | Human serum samples;/30 days (95%) | - | [ |
* 5-HT—serotonin; AA—ascorbic acid; AChE—acetylcholinesterase; Amp—Chronoamperometry; APAP—acetaminophen; AuE—gold electrode; AuNPs—gold nanoparticles; BSA—bovine serum albumin; β-CD—β- cyclodextrin; CFE—carbon fiber electrode; Chit—chitosan; ChOx—choline oxidase; cMWCNTs—carboxylated multiwalled carbon nanotubes; Cys—cysteine; DPV—differential pulse voltammetry; EDC—1-ethyl-3-(3-dimethylaminopropyl) carbodiimide; EPI—Epinephrine; GABA—Gamma-Aminobutyric acid; GCE—glassy carbon electrode; GlOx—glutamate oxidase; GlDH—glutamate dehydrogenase; Glu—glucose; Gluth—glutaraldehyde; HBH—p-hydroxybenzoate hydroxylase; HRP—horseradish oeroxidase; hPG—highly porous gold; ITO—Indium Tin Oxide; l-DOPA—3,4-dihydroxy-l-phenylalanine; LSV—l1inear sweep voltammetry; MEA—micromachined multi-electrode array; MWCNT—Multiwalled carbon nanotubes; MelB—meldola’s blue; NAD+—nicotinamide adenine dinucleotide; NAEs—nanowire array electrodes; Opd— o- phenylenediamine; PAM—polyacrylamide; PAMAM—poly (amidoamine); PB—Prussian Blue; PEG—pyrolytic graphite electrode; PEI—polyethyleneimine; PPD—poly (phenylene diamine); Py—pyrrole; PPy—polypyrrole; PGE—pencil graphit electrode; PoPD—Poly ortho- phenylendiamine; PPyNPs—polypyrrole nanoparticles; PANI—polyaniline; PtNPs—platinum nanoparticles; pTTBA = 2, 2:5,2-terthiophene-3-(p-benzoic acid); PtNPs—Pt nanoparticles; QPRT—quinolinate phosphoribosyl transferase; rGO—reduced graphene oxide; SHL—salicylate hydroxylase; SPCE—screen-printed carbon electrode; SWCNTs—single walled carbon nanotyubes; Th—thionine; Tyr—Tyrosinase; UA—uric acid; VACNTs—vertically aligned carbon nanotubes; ZnO NRs—ZnO nanorods.
Figure 5GlDH/NiePdePAM/GCE platform architecture. Reprinted from [156] with permission of Elsevier.
Figure 6Schematic illustration of the stepwise ACh biosensor fabrication process. Reprinted from [141] with permission of Elsevier.